ERBB2 and chronic myelogenous leukemia, BCR-ABL1 positive: From our previous work with these proteins in CML [31], and what has been published previously in HER2+ breast cancer [22,23], we decided to uncover their relevance as biomarkers or as therapeutic targets in other types of cancers.